title: Radiocontrast media. Regulatory aspects.
abstract: The FDA regulates the development, manufacturing, marketing, and postmarketing surveillance of radiocontrast and medical imaging agents, which it defines as drugs. In the current environment, the trend by many institutions toward cost consciousness and quantitative evaluation of all aspects of health care indicates that FDA regulations will represent only one of several regulatory forces that will affect the development and use of all drugs.
authors.affiliation: Degge Group, Ltd., Arlington, Virginia 22209-3109.
authors.forename: J K
authors.initials: JK
authors.lastname: Jones
mesh_terms: D002986:Clinical Trials as Topic; D003287:Contrast Media; D004353:Drug Evaluation, Preclinical; D004335:Drug and Narcotic Control / Q000379:methods*; D011358:Product Surveillance, Postmarketing; D012449:Safety; D014481:United States; D014486:United States Food and Drug Administration
chemical_list: D003287:Contrast Media